EMJ Cardiology 10 [Supplement 1] . 2022

In this issue

In an interview conducted by EMJ, a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for aficamten. A cardiac myosin inhibitor, aficamten targets the underlying pathophysiology of hypertrophic cardiomyopathy.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.